Nanoparticle-Based Treatment in Glioblastoma
Glioblastoma (GB) is a malignant glioma associated with a mean overall survival of 12 to 18 months, even with optimal treatment, due to its high relapse rate and treatment resistance. The standardized first-line treatment consists of surgery, which allows for diagnosis and cytoreduction, followed by...
Main Authors: | Diogo Roque, Nuno Cruz, Hugo Alexandre Ferreira, Catarina Pinto Reis, Nuno Matela, Manuel Herculano-Carvalho, Rita Cascão, Claudia C. Faria |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-08-01
|
Series: | Journal of Personalized Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2075-4426/13/9/1328 |
Similar Items
-
Highlighted Advances in Therapies for Difficult-To-Treat Brain Tumours Such as Glioblastoma
by: Nuno Cruz, et al.
Published: (2023-03-01) -
Antibody Delivery into the Brain by Radiosensitizer Nanoparticles for Targeted Glioblastoma Therapy
by: Omer Gal, et al.
Published: (2022-09-01) -
Advances in Glioblastoma Multiforme Treatment: New Models for Nanoparticle Therapy
by: Elif Ozdemir-Kaynak, et al.
Published: (2018-03-01) -
Insights into Multifunctional Nanoparticle-Based Drug Delivery Systems for Glioblastoma Treatment
by: Mohd Khan, et al.
Published: (2021-04-01) -
Synchronous Disintegration of Ferroptosis Defense Axis via Engineered Exosome‐Conjugated Magnetic Nanoparticles for Glioblastoma Therapy
by: Boyan Li, et al.
Published: (2022-06-01)